Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.
As of close of business last night, Capricor Therapeutics Inc’s stock clocked out at $11.01, up 6.17% from its previous closing price of $10.37. In other words, the price has increased by $6.17 from its previous closing price. On the day, 3.39 million shares were traded. CAPR stock price reached its highest trading level at $11.41 during the session, while it also had its lowest trading level at $10.1711.
Ratios:
To gain a deeper understanding of CAPR’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 6.55 and its Current Ratio is at 6.55. In the meantime, Its Debt-to-Equity ratio is 0.04 whereas as Long-Term Debt/Eq ratio is at 0.03.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Roth Capital on May 20, 2025, initiated with a Buy rating and assigned the stock a target price of $31.
On October 21, 2024, Piper Sandler started tracking the stock assigning a Overweight rating and target price of $35.
On May 17, 2024, Oppenheimer started tracking the stock assigning a Outperform rating and target price of $14.Oppenheimer initiated its Outperform rating on May 17, 2024, with a $14 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Sep 20 ’24 when Nippon Shinyaku Co Ltd bought 2,798,507 shares for $5.36 per share. The transaction valued at 14,999,998 led to the insider holds 7,090,351 shares of the business.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CAPR now has a Market Capitalization of 503242880 and an Enterprise Value of 359715200. For the stock, the TTM Price-to-Sale (P/S) ratio is 28.99 while its Price-to-Book (P/B) ratio in mrq is 3.94. Its current Enterprise Value per Revenue stands at 20.717 whereas that against EBITDA is -6.449.
Stock Price History:
The Beta on a monthly basis for CAPR is 0.84, which has changed by 0.7616 over the last 52 weeks, in comparison to a change of 0.11936104 over the same period for the S&P500. Over the past 52 weeks, CAPR has reached a high of $23.40, while it has fallen to a 52-week low of $3.52. The 50-Day Moving Average of the stock is 2.01%, while the 200-Day Moving Average is calculated to be -12.52%.
Shares Statistics:
It appears that CAPR traded 2.01M shares on average per day over the past three months and 4055620 shares per day over the past ten days. A total of 45.68M shares are outstanding, with a floating share count of 40.15M. Insiders hold about 12.16% of the company’s shares, while institutions hold 40.38% stake in the company. Shares short for CAPR as of 1745971200 were 10340629 with a Short Ratio of 5.16, compared to 1743379200 on 9303425. Therefore, it implies a Short% of Shares Outstanding of 10340629 and a Short% of Float of 25.759999999999998.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The market rating for Capricor Therapeutics Inc (CAPR) is a result of the insights provided by 6.0 analysts actively involved in the assessment.The consensus estimate for the next quarter is $0.6, with high estimates of $1.28 and low estimates of -$0.47.
Analysts are recommending an EPS of between $3.11 and -$1.91 for the fiscal current year, implying an average EPS of $0.61. EPS for the following year is -$0.68, with 6.0 analysts recommending between $1.0 and -$1.36.
Revenue Estimates
Based on 8 analysts’ estimates, the company’s revenue will be $91.72M in the next fiscal year. The high estimate is $259.35M and the low estimate is $25.95M.
